WGS GeneDx Holdings Corp.
Company Analysis
Latest News
🔴 GeneDx is trading 5.1% down today in pre-market as broad risk-off move hits U.S. futures
GeneDx is trading at $80.50 (-5.08%) after a broad risk-off move across U.S. equity futures. • S&P 500, Nasdaq Composite, and Dow futures are all lower. •...
🔴 GeneDx is trading 6% down today
GeneDx is trading 5.90% lower at $81.24 on August 31, 2026, with no clear company-specific catalyst identified. - No announcement, earnings update, analyst...
Casdin Capital increases GeneDx stake by 23%
Casdin Capital raised its stake in GeneDx Holdings (WGS) by 23.28% during the second quarter of 2026, according to a recent SEC filing. The investment firm,...
Bank of America boosts GeneDx stake, following surprise quarterly profit
Bank of America Corp DE increased its position in GeneDx Holdings Corp. during the first quarter. The bank purchased 102,456 additional shares, marking a 77.5%...
🟢 GeneDx rises 4.4% — Biotech Sector Continues Upward Trend on Strong Momentum
With Biotech (XBI) up 2.0%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🟢 GeneDx is trading 4% up today despite broader biotech weakness
GeneDx is trading at $82.85, up +4.02%, with no fresh company-specific announcement identified to explain the August 20 move. - Recent bullish context...
GeneDx Faces Fiduciary Breach Investigation, Following Revenue Guidance Cut
Lifshitz Law Firm is investigating GeneDx Holdings Corp. for potential breaches of fiduciary duties by its directors and officers. This follows several similar...
🔴 GeneDx is trading 4.8% down in pre-market with no clear company-specific catalyst
GeneDx is trading 4.8% down at $75.83 after no clear company-specific catalyst emerged in the latest overnight coverage. - Recent developments—the August 11...
🟢 GeneDx rises 4.3% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🔴 GeneDx is trading 4% down today — no credible company-specific announcement identified
GeneDx is trading 4.04% down at $79.06, reversing after closing at $82.39 on August 12, 2026, with no credible August 13 company-specific announcement...
🟢 GeneDx is trading 4% up today after exceeding Q2 expectations, reaffirming guidance, and announcing online exome testing
GeneDx (WGS) is trading 4.01% up now at $81.00 after several significant announcements on August 11, 2026: The company reported Q2 2026 adjusted net income...
🟢 GeneDx is trading 7% up today after Q2 revenue beat
GeneDx is trading at $74.39 (+7.04%) after a Q2 revenue beat and analyst support. - Q2 revenue reached $114.4 million, exceeding expectations; adjusted net...
GeneDx Beat Revenue Targets and Set Volume Records — So Why Are Investors Heading for the Exit?
Shares of GeneDx Holdings (WGS) dropped 8% to $62.43 in after-hours trading after the rare-disease genetic testing company delivered a Q2 that split cleanly...
🟢 GeneDx is trading 4.1% up today after reporting a return to adjusted profitability and strong Q2 revenue
GeneDx is trading 4.1% up now at $70.61 after reporting better-than-expected second quarter 2026 revenue and a return to adjusted profitability. • The company...
GeneDx hits fraud lawsuit deadline, following 50% stock price crash
August 3, 2026, marks the deadline for investors to seek lead plaintiff status in a securities fraud class action against GeneDx Holdings Corp. The lawsuit...
🟢 GeneDx is trading 10.5% up today after Q2 revenue beat and return to adjusted profitability
GeneDx is trading approximately 10.5% up at $75.00 in pre-market trading today after reporting a return to adjusted profitability and a second-quarter revenue...
🟢 GeneDx is trading 6.8% up today after Q2 revenue beat and reaffirmed guidance
GeneDx is trading at $72.50 (+6.84%) after reporting Q2 revenue of $114.4 million, which exceeded analyst expectations and highlighted strong operational...
🟢 GeneDx is trading 12% up today after Q2 earnings beat and return to profitability
GeneDx is trading 12% up at $76.00 after reporting second-quarter 2026 revenue of $114.4 million, beating analyst estimates and returning to adjusted...
🔴 GeneDx is trading 8% down today after GAAP EPS miss and reaffirmed 2026 guidance
GeneDx is trading 8% down at $62.43 in after-hours trading following the release of its Q2 2026 financial results, which showed a wider-than-expected GAAP...
GeneDx's second quarter revenue of $114.4M beat estimates, driven by 32% growth in exome/genome volume.
GeneDx reported second quarter 2026 revenue of $114.4 million, an 11% increase year-over-year, beating analyst expectations. The company reported a GAAP loss...